Next generation of immune checkpoint therapy in cancer: New developments and challenges, J Hematol Oncol, vol.11, p.39, 2018. ,
Emerging opportunities and challenges in cancer immunotherapy, Clin Cancer Res, vol.22, pp.1845-1855, 2016. ,
Emens LA and IMpassion130 Trial Investigators: Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer, N Engl J Med, vol.379, pp.2108-2121, 2018. ,
Turning cold tumors into hot tumors: Harnessing the potential of tumor immunity using nanoparticles, Expert Opin Drug Metab Toxicol, vol.11, pp.1139-11475, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01958583
Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study, J Clin Oncol, vol.36, pp.108-108, 2018. ,
Fluoropyrimidine and bevacizumab plus or minus atezolizumab as first-line treatment for BRAF wild-type metastatic colorectal cancer: Findings from the MODUL trial of biomarker-driven maintenance, p.19, 2018. ,
A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC), J Clin Oncol, vol.15, pp.6009-6009, 2018. ,
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy, Cancer Metastasis Rev, vol.30, pp.61-69, 2011. ,
The CDK4/6 inhibitor abemaciclib induces a T-cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade, Cell Rep, vol.22, pp.2978-2994, 2018. ,
Computational oncology--mathematical modelling of drug regimens for precision medicine, Nat Rev Clin Oncol, vol.13, pp.242-254, 2016. ,
Metronomics chemotherapy: time for computational decision support, Cancer Chemother Pharmacol, vol.74, pp.647-652, 2014. ,
Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine, Semin Cancer Biol, vol.35, pp.53-61, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01195547
Pharmacokinetics and pharmacodynamics-based mathematical modeling identifies an optimal protocol for metronomic chemotherapy, Cancer Res, vol.77, pp.4723-4733, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01789578
Mathematical modeling for phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients, Oncotarget, vol.8, pp.47161-47166, 2017. ,
Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: A phase 2 clinical trial, JAMA Oncol, vol.4, pp.93-97, 2018. ,
Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors, Clin Pharmacokinet, 2019. ,
Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer, Cancer Chemother Pharmacol, vol.73, pp.737-747, 2014. ,
A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patients, Sci Rep, vol.7, p.2714, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01606760
Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: A Lymphoma Study Association report, Blood, vol.129, pp.2616-2623, 2017. ,
Bevacizumab pharmacokinetics influence overall and progression-free survival in metastatic colorectal cancer patients, Clin Pharmacokinet, vol.55, pp.1381-1394, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01769811
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): A phase 1a, multicohort, dose-escalation trial, Lancet Oncol, vol.18, pp.587-598, 2017. ,
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, vol.366, pp.2443-2454, 2012. ,
Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer, Eur J Cancer, vol.109, pp.12-20, 2019. ,
Clinical pharmacokinetics of therapeutic monoclonal antibodies, Clin Pharmacokinet, vol.49, pp.493-507, 2010. ,